Technical overview for CME
The principle of complete mesocolic excision (CME) was first explicitly mentioned by Hohenberger [
1,
4] as the translation of the at that time already accepted total mesorectal excision (TME) technique for rectal cancer to colon cancer surgery. The principle of mesocolic excision aimed at meticulously separating the mesocolic from the parietal plane and at implying a true central ligation of affected arteries and veins. Most importantly, the concept includes sharp dissection along the embryonic planes without breaching the thin covering layer enveloping the lymphatic vessels and lymph nodes, in order to prevent tumor cell spillage. Following this concept, dissecting along the mesocolic plane leads to the very origin of the supplying arteries and accompanying veins, resulting in highly radical dissection with a maximum lymph node harvest. Noteworthily, and as a difference to the Japanese D3 lymphadenectomy concept, the extent of colon resection is also affected by mesocolic principles demanding at least 10 cm bowel length in both directions from the tumor site, which is further extended until the next main arterial pedicle. With focus on a very central dissection, the principle postulates manipulation in anatomically complex and vulnerable regions, for example, radical dissection along the duodenum and pancreatic head for right-sided colon cancer or complete dissection of the mesocolon at the lower edge of the pancreas for transverse colon cancer. In open surgery, the dissection is traditionally directed from lateral to medial and by application of electrocautery. The true benefit of CME is still discussed, as the oncologic outcome was not reported to be superior in some studies; however, and consistently, specimen parameters such as included lymph nodes and length of the vascular pedicle show better results, suggesting at least theoretical superiority [
5,
6]. Additionally, West et al. identified a larger mesocolic plane as measured in square millimeters with patients after mesocolic resection [
7]. In a recent comprehensive analysis, Bertelsen was able to show a 10% improvement in 5‑year disease-free survival [
8], data which have been confirmed by others [
3]. However, most of the currently available knowledge has been gained from open surgery series, but can these results and the concept of mesocolic dissection also be transferred to minimally invasive surgery?
Naturally, in laparoscopic or robotic surgery, the mentioned principles of CME have to be maintained [
9], which can be difficult, for example when following the lateral-to-medial approach, because of the loose specimen interfering with the paramount central dissection. Accordingly, a medial-to-lateral approach is chosen as the preferred line of dissection in most reported series. Despite this modification, dissection along the central vasculature, especially for right-sided colonic cancer of the superior mesenteric artery and vein, remains challenging and is a reason for the occasionally reported high complication rates [
10]. Accordingly, several modifications for minimally invasive CME have been published to ease exposure of the central anatomy and to reduce the risk of complications, with the most relevant ones being outlined briefly in the following.
For right-sided cancer the dissection posterior to the ileocolic root with exposure of the inferior aspect of the duodenum is generally chosen as the first step. This can either be achieved by direct access from medial [
11] or by lifting up the entire mesenteric root via an uncinate-first approach [
12] or by first accessing the ileocolic junction in the bottom-to-up technique [
13]. Independently of the access route, this first step proceeds until reaching the correct avascular layer between the mesocolic and parietal fascia (Toldt’ fascia [
14]). Dissection is continued while spanning the mesocolic plane ventrally. A well-tempered traction and countertraction during this step is paramount to keep the correct dissection line and not to tear the enveloping skin layer. Undermining the central aspect of the right mesocolon supports identification of the ileocolic and superior mesenteric vessels. Central dissection of the ileocolic artery and vein is followed by meticulous cephalad preparation of the superior mesenteric vessels and dissection of the neighboring branches, mainly the gastro-pancreatic-colonic trunk of Henle (if present) and the middle colonic artery. The safe control of the mesenteric root in general requires dissection from below or along the superior mesenteric axis and from above via the omental bursa after transection of the gastrocolic vein. Some authors prefer to start first with exposure of the right gastroepiploic vessels and the trunk of Henle from above and via the omental bursa before dissecting along the superior mesenteric axis, for the high vascular variability and vulnerability of this region [
15]. After vascular dissection, the operation is continued by resecting the involved colonic segment and subsequent anastomosis of bowel ends either via a small abdominal incision or intracorporally.
In left-sided cancer and with only two main vessels (inferior mesenteric artery and vein) demanding for central dissection, the minimally invasive approach is less complex, but also requires a careful division of the mesentery in the proximity of the duodenum and pancreatic tail [
16]. As in right-sided cancer and opposite to open surgery, a medial-to-lateral approach first accessing the central vasculature has become the standard [
17] and is correlated with lower complication rates and shorter OR times and hospital stay. Robotic surgery herein follows the principles of laparoscopic surgery [
18], with the bottom-to-up principle gaining popularity due to its better exposure of central structures [
13,
19].
Results of open and laparoscopic CME as a benchmark
With the introduction of mesocolic resection, Hohenberger published a series of 1329 consecutive patients who were operated on in a single center from 1978 to 2002 and who were analyzed for overall results and for the effect of CME on oncologic results by splitting the entire cohort into three subgroups according to the date of operation [
1]. In this series, overall complication rates amounted to 19.7%, with 2.6% leakages, 0.9% bleedings, 0.8% ileus, 0.4% fistulas, and 1.4% abscesses. The already excellent results for tumor control improved within the reported timespan from 6.5% to 3.4% for local recurrence and from 82.1% to 89.1% for disease-free survival after 5 years. The mean number of lymph nodes in this series amounted to 32. In a second publication from the same group, Croner confirmed these excellent results in another 596 patients with a morbidity rate of 21.1%, leakages in 3.4%, and abscesses in 0.8%. The 5‑year disease-free survival remained 89.9% over all stages. In a propensity score-match analysis, Kotake compared the outcome of D2 and D3 lymphadenectomy (following the relevant principles of CME) in right- and left-sided colon cancer with 3425 patients for each cohort [
20]. He registered an increase in resected lymph nodes, with 22.3 nodes found after extended resection and a 5-year overall survival of 94.5%. Another larger publication is available from Bertelsen and included 364 patients after CME for colon cancer [
8]. In his report, 4‑year disease-free survival was calculated as 85.8% with a mean score of 36.5 lymph nodes in analyzed specimens. Interestingly, only 82% of patients in the CME group were finally attested to have a complete mesocolic excision. Merkel published a retrospective study comparing CME to conventional resection including 1099 patients who underwent mesocolic excision for colonic cancer [
21]. With complication rates of 21.3% and anastomotic leakages of 3.1%, his results are comparable to those of Hohenberger et al., as are the values for disease-free survival (80.9–95.2% for stage I–II and III) and local recurrence (1.1–4.1% for stage I–II and III).
With these results for open surgery as a benchmark, the results of laparoscopic mesocolic excision shall be displayed evaluating whether the improvements of CME have yet been fully transferred to minimally invasive surgery. Noteworthily, recent literature on laparoscopic mesocolic resection focused almost exclusively on right-sided colon cancer.
A total of 600 patients were included in the largest study from Siani, which was published in 2017 [
22]. With 81% of patients having undergone a pathologically confirmed complete mesocolic resection, disease-free survival and local recurrence rates after 5 years accounted for 78.3% and 6.4%, respectively. With a mean of 27.3 lymph nodes harvested, the extent of lymph node dissection was comparable to open series. The overall complication rate seemed relatively high at 35.5%, but accounted mostly for wound (10.6%) or urinary tract (6%) infections or pneumonia (9.8%). Anastomotic leakages were registered in only 2.5% of patients.
The data from Han on 177 laparoscopically performed laparoscopic CME [
23] similarly revealed outcomes equivalent to the mentioned open series with a disease-free survival after 5 years of 80.2% and a rate for local recurrence as low as 2.8%. With an overall complication rate of 13%, this series shows quite favorable results, although the number of lymph nodes removed reached only 15.2. Almost 3% of patients required conversion to open surgery. The publication of Wang favorably conforms to the latter, with low complication rates (16.3%) and a disease-free survival of 81.3% (3 years) after having removed 23.3 lymph nodes [
24]. With only one anastomotic leak among 172 patients, the leakage rate averaged 0.6%. In this article, chylous fistulas were observed in 12.7% of patients. 168 patients were included in the retrospective analysis from Shin, who—after having removed a mean of 27.8 lymph nodes—achieved a disease-free survival at 5 years of 95.2% for patients with stage II and 80.9% for patients with stage III, and an overall local recurrence of 3.6% [
25]. Shin found an average complication rate of 17.8%, with anastomotic leakages in 5.9%. Having adapted laparoscopic surgery for mesocolic excision of colon cancer, Takahashi translated his experience to single-site surgery which he analyzed in 202 retrospective cases [
26]. With a morbidity rate of 10%, 0.5% leakages, and 23.5 lymph nodes removed, his data are in line with the previously mentioned series. Oncologic data and long-term results, however, are not available for this report.
In conclusion, laparoscopic CME seems feasible, with local recurrences in 0–6% and a disease-free survival after 5 years between 78 and 88%. Conversion rates range from 0 to 18%, while complications were registered in 10–35% of patients.
Results of robotic-assisted surgery for mesocolic excision
Although data are still insufficient and randomized trials are lacking, one might permissively deduce laparoscopic surgery to be more or less equivalent to open CME, at least for the reported parameters. However, conversion rates in some of the reported studies are deemed too high, reaching up to 17.8%. Despite being discussed as extensive and complex surgeries, particularly severe complications range at a comparable percentage, while minor complications such as wound infections are reduced. Thus, the benchmark for robotic surgery has obviously been set at a high level already.
The most relevant study on robotic mesocolic excision for colon cancer was published in 2018 by Spinoglio [
27], when he compared the robotic with the laparoscopic approach. In a 1:1 evaluation, 101 patients were retrospectively analyzed in each group for intraoperative, postoperative, and oncologic results. Intraoperatively, he noted an approximately 40 min longer operative time for the robotic excision (279 vs. 236 min), albeit with a continuous decrease over time suggesting that the learning curve was not yet passed completely. However, the estimated final duration for robotic CME remained longer than for laparoscopy (about 250 min). Assessed specimen parameters did not reveal any difference. Of note, harvested lymph nodes amounted to 28.2 vs. 30.4 (robotic versus laparoscopic,
p = 0.188), thus in a comparable and satisfying range. As a relevant aspect, conversion rates were lower in the robotic group (0% vs. 7%,
p = 0.014). Postoperative complication rates, mostly Clavien–Dindo stage I–II, proved equivalent (27.7 vs. 33.6,
p = 0.360) and they observed one anastomotic leak and one massive postoperative bleeding in each group. Concerning the oncologic outcome, 5‑year disease-free survival was comparable in both groups, with 85% in the robotic and 83% in the laparoscopic group (
p = 0.58). For subgroup analysis in stage III patients, there was a slight but non-significant advantage in the robotic group (81% versus 68%,
p = 0.122). The authors finally concluded that robotic surgery for mesocolic excision with intracorporal anastomosis is feasible even within the learning curve and suggest it as a valuable option for difficult surgeries while offering a low conversion rate.
Another recently published study by Yozgatli et al. from Turkey compared results of 96 patients for robotic (
n = 35) versus laparoscopic CME for right-sided cancer [
28]. Again, operation times were significantly longer for robotic surgery and even twice as long as in the laparoscopic group (286 versus 132 min,
p < 0.01). The conversion and peri- and postoperative complication rates (29% versus 25%,
p = 0.67) were equal between the groups, with none versus three anastomotic leakages in disfavor of the laparoscopic group; the number of removed lymph nodes turned out to be significantly higher after robotic surgery (41 vs. 33,
p = 0.04), as was the length of the vascular pedicle (13 vs. 11 cm,
p = 0.02).
Beside these comparative studies, some case series on robotic mesocolic excision have been published. Exemplarily, Petz presented a series of 20 consecutive patients operated on by a suprapubic robotic approach with the trocars inserted in a horizontal line only a few centimeters above the pubic bone [
29]. After a mean operative time of 249 min and no conversions, he was able to remove a median number of 42 lymph nodes. Postoperatively, only 10% complications occurred, but no anastomotic leaks. The same technique was applied by Schulte am Esch in 17 patients and compared to the traditional medial-to-lateral approach in 7 patients [
19]. The operation times in both groups were about 285 min. Complication (33.4% and 42.9%,
p = 0.633) and insufficiency rates (none in either group) did not provide a difference between the techniques, while the number of lymph nodes in the bottom-to-up group reached a significantly higher level, with 40 removed LN compared to 16 LN in the standard group (
p < 0.01). The authors conclude the suprapubic technique to be an oncologically superior technique to the standard medial-to-lateral directed technique, which should be considered the new oncological standard.
The publication of Yang included 66 patients who were operated on with a robotic “superior mesenteric vein” approach, which displayed a subtle modification of the conventional medial-to-lateral approach [
30], accessing the SMV first before dissecting the ileocolic trunk. For 66 patients he ended up with a mean operative time of 192 min, a median lymph node harvest of 32, and a complication rate as low as 7.6%. He did not observe any anastomotic leakage and only one conversion.
A “top-down-no-touch” technique was recently introduced by Hamzaoglu, which starts with dissection of the omental bursa for early identification and preservation of the gastrocolic trunk and the right gastroepiploic arcade [
15]. After dissecting the branches of the middle colic artery, the procedure is continued as previously published from bottom-to-up, starting at the ileocolic junction until reaching the ileocolic artery and vein. In a series of 10 patients, he published operative times of 312 min, low complication rates, and a number of dissected lymph nodes of around 45.
For non-right-sided cancer, two publications exist: one for mesocolic transverse colon resection [
31] and one for left-sided mesocolic excision [
32]. For carcinoma of the transverse colon, Ozben summarized his experiences in 29 patients of whom 12 patients underwent extended right colectomy, 10 extended left colectomy, 6 subtotal colectomy, and 1 total colectomy [
31]. Operations were completed within a mean time of 322 min, postoperative complications were registered in 24% of patients, the rate of patients with complete mesocolic resection was calculated as 79%, there were no conversions. Despite the extended resection, the number of lymph nodes removed amounted to 37 in extended colectomy and 71 in total colectomy patients. Ozben concluded robotic mesocolic resection for cancer of the transverse colon to be feasible, offering a good surgical quality. A comparative analysis of 20 robotic mesocolic resections for left-sided cancer with 53 laparoscopic cases was published by Kim from Korea [
32]. With no differences concerning basic patient data, operative results showed a significantly longer OR time for robotic surgery (170 min versus 117 min,
p < 0.01), equality for postoperative complications (20% versus 12%,
p = 0.278), no leakages in either group, and a lymph node count of 21 after robotic and 22 after laparoscopic surgery (
p = 0.629). No significant differences were seen in any other assessed parameters. Kim concludes robotic surgery for splenic flexure and descending colon cancer to be an efficient approach. An excerpt of relevant studies and patient outcomes is given in Table
1.
Table 1
Relevant studies on robotic vs. laparoscopic CME for colonic cancer
| 2012 | Lap. CME/R | 52 | 136 (105–167) | 22 (18–29) | 30.7 | 4 | 2 | n.a. | 92 (3-year) | 0 |
| 2013 | Lap. CME/R | 177 | 133 (±36 min) | 15.2 (±10) | 13 | 3.95 | 3 | n.a. | 80.2 | 2.8 |
| 2014 | Lap.CME/R | 168 | 196 (±61.2) | 25.5 (3–76) | 17.8 | 5.9 | 17.8 | n.a. | 88.3 | 3.6 |
| 2017 | Lap.CME/R | 600 | 149 (±29 min) | 27.3 (±3) | 35.5 | 2.5 | n.a. | 81 | 78.3 | 6.4 |
| 2017 | Lap. CME/R | 172 | 113.5 (±34 min) | 32.2 | 16.3 | 0.6 | 0 | n.a. | 81.3 (3-year) | n.a. |
| 2017 | Lap.CME/R | 202 | 193 (157–234) | 23.5 | 10 | 0.5 | n.a. | n.a. | n.a. | n.a. |
| 2017 | Robotic CME/R | 20 | 249 (194–330) | 40 (19–67) | 10 | 0 | 0 | n.a. | n.a. | n.a. |
| 2018 | Robotic CME/R | 12 | 312.1 ± 93.9 | 45.2 ± 11.1 | 6.9 | 0 | 0 | 75 | n.a. | n.a. |
| 2018 | Robotic CME/R | 101 | 279 (±80 min) | 28.2 (±10.6) | 22.7 | 1 | 0 | n.a. | 85 | n.a. |
| 2019 | Robotic CME/R | 17 | 283 (±87.9) | 40.2 (±17) | 33.4 | 0 | 0 | n.a. | n.a. | n.a. |
| 2019 | Robotic CME/R | 66 | 192 (172–240) | 32 (25–40) | 7.6 | 0 | 1.5 | n.a. | n.a. | n.a. |
| 2019 | Robotic CME/R+T | 35 | 286 (±77) | 41 (±12) | 29 | 0 | 0 | n.a. | n.a. | n.a. |
| 2016 | Robotic CME/T | 29 | 321.7(± 111.3) | 37–71 | 24 | 0 | 0 | 79 | n.a. | n.a. |
| 2018 | Robotic CME/L | 20 | 170 (±29 min) | 21 (±7) | 20 | 0 | 0 | n.a. | 90.2 (2-year) | 0 (2y) |
To summarize these results in comparison to laparoscopic surgery, robotic surgery tends to have a higher lymph node count and lower conversion rate, which is paid for by longer operative times. Due to missing follow-up data in most of the available series, any conclusion on oncologic equivalence for this comparison seems undue.